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Abstract Restoration and repair of articular cartilage injuries remain a challenge for orthopaedic
surgeons. The standard first-line treatment of articular cartilage lesions is marrow
stimulation; however, this procedure can often result in the generation of fibrous repair
cartilage rather than the biomechanically superior hyaline cartilage. Marrow stimula-
tion is also often limited to smaller lesions, less than 2 cm2. Larger lesions may require
implantation of a fresh osteochondal allograft, though a short shelf life, size-matched
donor requirements, potential challenges of bone healing, limited availability, and the
relatively high price limit the wide use of this therapeutic approach. We present a
straightforward, single-stage surgical technique of a novel reparative and restorative
approach for articular cartilage repair with the implantation of a cryopreserved viable
osteochondral allograft (CVOCA). The CVOCA contains full-thickness articular cartilage
and a thin layer of subchondral bone, and maintains the intact native cartilage
architecture with viable chondrocytes, growth factors, and extracellular matrix
proteins to promote articular cartilage repair. We report the results of a retrospective
case series of three patients who presented with articular cartilage lesions more than
2 cm2 and were treated with the CVOCA using the presented surgical technique.
Patients were followed up to 2 years after implantation of the CVOCA and all three
patients had satisfactory outcomes without adverse events. Controlled randomized
studies are suggested for evaluation of CVOCA efficacy, safety, and long-term
outcomes.
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Affecting as many as 900,000 people annually in the United
States, articular cartilage injuries remain a therapeutic chal-
lenge for orthopaedic surgeons.1,2 The most common treat-
ment for articular cartilage damage is marrow stimulation.
This reparative approach entails creation of channels to the
subjacent marrow by abrading or perforating the subchondral
bone.1Marrow blood ascends up to the lesion bed, resulting in
a blood clot containing mesenchymal stem cells (MSCs).
Although it was originally believed that these MSCs would
differentiate into chondrocytes and produce hyaline cartilage,
more often fibrocartilage is formed.2,3 Fibrocartilage princi-
pally contains type I collagen rather than type II collagen
(principle constituent of hyaline cartilage), resulting in poor
long-term biomechanics. Although marrow stimulation may
work well in small, shouldered lesions (< 2 cm2), it often fails
over time in larger lesions.1,2 Thus, although traditional mar-
row stimulation is easy to perform, minimally invasive, safe,
and inexpensive, it has limited efficacy and often requires
additional, invasive, and expensive revision surgeries.
Osteochondral allografts have longbeen successfullyusedas
a restorativeapproach to treat articularcartilagedamage. These
articular cartilage and subchondral bone allografts are typically
harvested as cylinders and can be combined to treat larger
osteochondral lesions. The clinical use of fresh osteochondral
allografts began more than 40 years ago and has shown good
results.4,5However, fresh stored osteochondral allograftsmust
be used within 30 days due to rapid and significant decline of
chondrocyte viability postharvest.6–9 In addition, osteochon-
dral allograft implantation requires precise size and contour
matching between donor and recipient tissues. The short shelf
life, size-matched donor requirements, challenge of allogeneic
bone healing, limited availability, and the relatively high price
limit the use of fresh stored osteochondral allografts.
Here,wepresentanewoption that combines reparative and
restorative approaches for articular cartilage repair. The cryo-
preserved viable osteochondral allograft (CVOCA) (Cartiform,
Osiris Therapeutics, Inc) contains full-thickness articular car-
tilage and a thin layer of subchondral bone (< 500 µm,
estimated by histological analysis). The CVOCA maintains the
intact native cartilage architecture with endogenous viable
chondrocytes, chondrogenic growth factors, and extracellular
matrix proteins to promote articular cartilage repair.10 Pores
traverse the thickness of theosteochondral allograft, giving the
CVOCA the versatility to be flexible to match the contour of
various articular cartilage surfaces. The pores also enable the
cryopreservation solution to better penetrate the thickness of
the allograft, helping to preserve a high percentage of viable
chondrocytes while in storage at  80°C over its 2-year shelf
life.10 The CVOCAbuilds uponmore than 40 years of safety and
efficacy of fresh osteochondral allografts as a restorative
approach to articular cartilage repair.11–14 However, the
CVOCA was designed as an adjunct to marrow stimulation.
When the CVOCA is used with marrow stimulation, MSCs
released from the patient’s bone marrow are expected to
initiate a reparative response within the pores of the CVOCA
in the lesion in addition to the restorative approach from the
allograft cartilage itself.10,15 The CVOCAmay also be usedwith
light abrasion to notweaken the subchondral bone, similar to a
traditional osteochondral allograft but as an off-the-shelf
product. The CVOCA is currently available in multiple sizes
ranging from0.8 to 4.5 cm2withprices from$3,500 to $11,000.
Using the straightforward, single-stage surgical procedure
described here, the CVOCA may offer an important additional
approach to articular cartilage restoration.
Surgical Technique
The lesion is defined by circumscribing the damaged cartilage
slightly into thesurroundinghealthy tissuewithaNo.11orNo.
15 blade, creating vertical lesionwalls (►Fig. 1A) in a manner
as used for cell therapy (e.g., autologous chondrocyte implan-
tation). A curette is used to debride any residual articular
cartilage within the circumscribed boundary, completely
removing the calcified layer and debriding back to a point
where the cartilage–bone interface is stable (►Fig. 1B, C). The
healthy articular cartilage surrounding the lesion should be
moistened with normal saline often during the surgery.2
Next, the surgeon may choose to perform controlled mar-
row stimulation of the bony bed. To limit the damage to the
subchondral bone, finer drill bits or wires are recommended.
Fig. 1 (A–C) Intraoperative views of an articular cartilage lesion on the medial femoral condyle. The damaged cartilage is removed and the
lesion bed is prepared for treatment.
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The marrow stimulation holes are placed at the perimeter of
the lesion first, followed by additional holes inside at 2 to
3 mmintervals. Forpatella lesions, a smalldrill bitmaybeused
due to the hardness of the subchondral bone. Alternatively,
rather than creating holes, the base may be lightly abraded,
removing only superficial bone from the subchondral bone
plate to expose microscopic vascular arcades that create a
“blush of blood”within this abraded region. Cooling irrigation
is suggested to minimize thermal damage.
Once the lesion bed is prepared, a template of the lesion is
made using either sterile foil or paper (►Fig. 2A). Appropriate
CVOCA sizes should be selected so that the CVOCA covers the
entire lesion. Multiple sizes, including both circular and
rounded rectangle shapes, provide options to fit a majority
of lesions. For larger lesions, multiple CVOCAs can be
trimmed and assembled on the template, placed side to
side without stacking, to cover the entire defect. The CVOCA
comes scored with a linear mark on the “deep” side to be
approximated to the patient’s bone to help the surgeon keep
the graft oriented properly during the implantation. This
orientation is key as the base will unlikely heal to the
superficial cartilage zone if the CVOCA is inverted. The
surgeonmaymark the superficial side with a sterile marking
pen for easy graft side recognition, ensuring that the pen is
not chondrotoxic prior to use. The CVOCA is trimmed using a
No. 15 blade or iris scissors to fit the custom template. The
CVOCA is then trial fitted to the lesion to verify shape and
size. The entire CVOCA should be in direct contact with the
patient’s underlying bone, closely apposed to the walls, and
not proud to the surrounding cartilage. Nonmetallic and
nonbone reactive suture anchors may be used to fix the
CVOCA in place. Anchors which require a 3-mm pilot hole or
smaller should be chosen, and threaded with two 4–0 to 6–0
resorbable sutures (►Fig. 2B). The placement of the anchors
is location dependent. A trochlea lesion requires placement
of a central anchor to pull the graft down into place to take on
the concave contour. Anchors around the periphery are
beneficial for convex surfaces. The 4–0 to 6–0 resorbable
sutures may also be used to secure the CVOCA to the
surrounding cartilage. Damage to the native cartilage is
prevented by following the curve of the needle. A thin,
tapered, 17-mm, half circle needle is recommended.
Following placement of any suture anchors, the largest
CVOCA is placed and secured, followed by any additional
CVOCAs. The suture from each anchor is threaded through
the holes in the CVOCA and tied tight enough to secure the
CVOCA to the bone but not so tight as to cause damage
(►Fig. 2C). The security of the graft construct is tested with
palpation and by putting the joint through a range of motion
(ROM) and observing movement of the graft. Fibrin glue is
applied between the CVOCA periphery and the native carti-
lage walls, avoiding the holes in the graft, as a final step to
secure the graft in place. Adherence to a rehabilitation
protocol should be emphasized as failure to do so can lead
to graft failure. In the case of immobilization, deep venous
thrombosis prophylaxis measures should be taken.
Patients and Methods
Patients were considered for treatment if they presented
with contained or uncontained focal articular cartilage le-
sions of the medial femoral condyle, the lateral femoral
condyle, the trochlea, or the patella. Additional requirements
for treatment included the presence of healthy surrounding
articular cartilage with no degenerative articular cartilage
disease, signs and symptoms consistent with the location of
the chondral lesion, a lesion more than 2 cm2, and a physio-
logic age of younger than 60 years. Prior to surgical implan-
tation of CVOCA, an arthroscopic assessment was performed
on each patient to assess the articular cartilage lesion of
interest and to evaluate the health of surrounding articular
cartilage. Three patients with focal articular cartilage lesions
were treated with the CVOCA. Magnetic resonance imaging
(MRI) was evaluated by an external radiologist. Per regula-
tions of the Department of Health and Human Services, a
retrospective report containing three cases does not require
Institutional Review Board approval. All HIPAA identifiers
were removed from the data.
Patient 1
Patient 1 is a 52-year-old male ski instructor who presented
with anterior cruciate ligament (ACL) deficiency, a large
medial meniscus tear, and a 2.5 cm  1.5 cm (3.75 cm2)
contained grade IV osteochondral defect on the medial
Fig. 2 Intraoperative views of the medial femoral condyle, demonstrating (A) sizing and (B, C) implanting the cryopreserved viable
osteochondral allograft.
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femoral condyle of the left knee. He underwent a superior
compartment synovectomy, an ACL reconstruction using a
bone–tendon–bone allograft, a repair of the medial menis-
cus, marrow stimulation of the medial femoral condyle, and
an open CVOCA transplant to the medial femoral condyle of
the left knee.MRIwas performed on patient 1 preoperatively
as well as at 1, 3, 6 months, and 1 year postoperatively.
Patient 2
Patient 2 is a 20-year-old male college student who presented
with a 2.0 cm  2.5 cm (5.0 cm2) osteochondral defect on the
tibial plateau following a twisting injury of the left knee from
skiing. He underwent an intra-articular synovectomy, debri-
dement of his articular cartilage lesion,marrow stimulation of
the lateral tibial plateau lesion, and arthroscopic-assisted
CVOCA transplant to this area in the lateral tibial plateau of
the left knee. The graft was held in placewith peripheralfibrin
glue. The lateral collateral ligament was taken down proxi-
mally for access as seen and repaired with a malleolar screw.
MRI was performed on patient 2 preoperatively as well as at
1 month and 1 year postoperatively.
Patient 3
Patient 3 is a 28-year-old female who presented with an
osteochondral defect on the medial femoral condyle of the
left knee following a traumatic bicycle injury. She underwent
diagnostic arthroscopy with marrow stimulation of the
medial femoral condyle, and an open CVOCA transplant to
the contained lesion of themedial femoral condyle of the left
knee. The lesion sizewas 1.5 cm  2.2 cm (3.3 cm2). MRI was
performed on patient 3 preoperatively as well as at 1 and 6
months postoperatively.
Results
Patient 1
Preoperative 3T MRI showed an osteochondral defect within
the medial femoral condyle with bone marrow edema
(►Fig. 3A, AA). After the outpatient procedure, patient 1
underwent a routinepostoperative course. Hewent to therapy
at 3 weeks and began weight bearing at 8 weeks. The patient
continued his progress with an increase in ROM and returned
to activities of daily living, including employment and sports
activity. He returned to work on crutches within 1 week and
was driving comfortably at that time. As shown in ►Fig. 3, a
1-month MRI showed that the CVOCAwas in place with early
evidence of resolution of subchondral edema. The CVOCA
exhibited good surface congruity against adjacent cartilage,
but the edges could still be visualized and areas of alteration in
the underlying subchondral bone plate were still present. At 3
months, further integration of the CVOCAwas evident byMRI.
TheCVOCAwas inplace and further reductionof bonemarrow
edema was observed. The 6-month follow-up MRI showed
improved CVOCA integrationwith a fewareas of altered signal
characteristics in the CVOCA cartilage remaining when com-
pared with the adjacent host cartilage (►Fig. 3D, DD). At
1 year, the signal within the CVOCA was more equivalent to
adjacent host cartilage, the CVOCA appeared to completely fill
the lesionwith good incorporation and surface congruity, and
the subchondral edema had resolved (►Fig. 3E, EE). Compar-
ison of the 1-, 3-month, and 1-year axial cut MRIs showed
progressive incorporation of the CVOCA over time (►Fig. 4).
The patient’s ability to return to sports began at 6months and
increased all the way up to 1 year when he was skiing and
surfing. He continued to progress and improve up to 2 years.
His motion was complete and his pain was intermittent at
most, with a pain-free outcome at 2 years.
Patient 2
The preoperative 3TMRI showed an osteochondral defect of the
lateral tibial plateau with bone marrow edema (►Fig. 5A, AA).
Patient 2 was on crutches and returned to school the week
following surgery. Hewent to physical therapy at school and he
remained non-weightbearing for 8 weeks. In the 1-month
follow-up MRI, the lesion was filled with good surface con-
gruity, although the edges of the CVOCA were visible and
the subchondral bone plate exhibited areas of alteration
(►Fig. 5B, BB). The patient continued with his classes and
progressed to sports 6 months after surgery. His progress
continued to improve to a full ROM with minimal pain and
Fig. 3 Coronal and sagittal magnetic resonance images of patient 1 who was treated for a medial femoral condyle lesion, taken (A, AA)
preoperatively, (B, BB) at 1 month postoperatively, (C, CC) at 3 months postoperatively, (D, DD) at 6 months postoperatively, and (E, EE) at
1 year postoperatively.
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hisprogress increasedonthebasketball court.The1-year follow-
up MRI showed complete fill with good surface congruity and
CVOCA/host incorporation; only a couple small areas of altered
signal characteristics were still evident within the CVOCA
(►Fig. 5C, CC). Approximately 1 year after the surgery, the
patient tore his contralateral ACL andwent through reconstruc-
tion. Two years after surgery, his operated knee had minimal
pain and complete unrestricted function.
Patient 3
The preoperative MRI showed an osteochondral defect about
themedial femoral condylewithminimal bonemarrowedema
(►Fig. 6A, AA). Patient 3 progressed after the outpatient
surgery to return to work at 3 weeks in a non-weightbearing
fashion. One month MRIs showed persistence of the CVOCA
with near complete fill and good surface congruity, but in-
creased fluid signal was noted in the underlying bone
(►Fig. 6B, BB). The patient was walking at 8 weeks and she
resumed her walking exercise patterns at 6 months after
surgery. The 6-month MRIs showed improvements in the
subchondral bone and continued integration of the CVOCA
(►Fig. 6C, CC). The patient continued to flourish at work with
minimal complaintsofpainwhengoingupanddownstairsand
minimal clinical symptomology. Sheoccasionallyhadeffusions
and pain at the end of long days of walking. Her WOMAC
(Western Ontario and McMaster University Osteoarthritis In-
dex)and IKDC(InternationalKneeDocumentationCommittee)
were above the 90th percentile at 2 years after surgery.
Discussion
A CVOCA was recently developed as a new treatment for
articular cartilage lesions. The CVOCA is the only viable
cartilage repair product on the market in the United States
that can be stored for an extended period for immediate,
point-of-care use. The CVOCA has been utilized to treat
articular cartilage lesions since 2012. The only clinical
peer-reviewed publications to date are a case report in the
knee and a technique article for the ankle.15,16 Future con-
trolled randomized clinical studies measuring functional
Fig. 5 Coronal and sagittal magnetic resonance images of patient 2 who was treated for a lateral tibial plateau lesion, taken (A, AA)
preoperatively, (B, BB) at 1 month postoperatively, and (C, CC) at 1 year postoperatively.
Fig. 4 Axial magnetic resonance images of patient 1 who was treated for a medial femoral condyle lesion, taken (A) at 1 month postoperatively,
(B) at 3 months postoperatively, and (C) 1 year postoperatively.
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outcomes by validated methods are required to prove safety
or efficacy of the CVOCA. The value of this study is a detailed
description of the unique implantation technique for the
CVOCA and outlining its application for repair of cartilage
lesions at different sites in the knee through a summary of
three clinical cases. The primary limitations of this case
report are the small number of patients (three) with pa-
tient-reported outcomes and relatively short-term follow-up
(2 years). However, these patientswere someof thefirst to be
treated with this new type of allograft and we believe the
presentation of these initial outcomes provides valuable
information to other surgeons considering using this new
technique.
Although the surgical technique for marrow stimulation is
very straightforward, the fibrocartilage that fills the lesion
often breaks down over time leading to poor long-term out-
comes, especially in older patients (> 40 years old) and in
larger lesions (> 2 cm2).17–20 The surgical technique for the
implantation of the CVOCA builds upon the surgical technique
for marrow stimulation and can be performed without much
added time or difficulty for an orthopaedic surgeon who is
comfortable performing marrow stimulation alone. The
CVOCA must simply be trimmed to fit the debrided lesion
and secured in place with sutures and/or suture anchors. The
addition of the CVOCA to a lesion treated with marrow
stimulation has the potential to expand the lesion size able
to be treated, as the CVOCA provides a microenvironment
throughout the lesion that is favorable forMSCchondrogenesis
and is expected to result in the formation of hyaline cartilage
throughout the lesion rather thanfibrocartilage.10 In this sudy,
lesions ranging from 3.3 to 5.0 cm2were treatedwithmarrow
stimulation augmented with the CVOCA. Multiple CVOCA
units can be combined to treat lesions as large as 10 cm2. It
is important to consider that the CVOCA adds to the cost of a
marrow stimulation procedure, especially in cases involving
large lesions wheremultiple grafts are required. The potential
clinical benefits should therefore be considered carefully and
weighed against the added procedural cost for each case.
When lesions are properly selected, patients treated with
marrow stimulation generally report symptomatic improve-
ment over the first 2 years, similar to the improvements
reportedhere.1However, deterioration in functionaloutcomes
is often evident starting at 18 months following marrow
stimulation treatment.1 This decline is attributed to incom-
plete defect fill, poor integration of the repair tissue with the
surrounding articular cartilage, and the inferior wear charac-
teristics of the fibrocartilage repair tissue.1,20–22 In contrast,
thepatients treatedwithmarrowstimulationaugmentedwith
the CVOCA exhibited near complete fill with good surface
congruity against adjacent cartilage as early as 1 month fol-
lowing surgery according to MRI analysis. In another recently
published case study, a trochlear lesion treated with marrow
stimulation plus the CVOCA exhibited significantly more hya-
line cartilage repair tissue (85%) than a lesion treated with
marrow stimulation alone (5% hyaline cartilage) at 9 and
8 months, respectively, following surgery when biopsies
were collected and analyzed.15 The patient treated with the
CVOCA reported resolution of pain and returned to normal
activity, whereas the patient treatedwithmarrow stimulation
alone requireda revision surgery.15 In theonlyotherpublished
cases to date, Tan et al described improvements in pain scores
for four patients treatedwithmarrow stimulation augmented
with the CVOCA for talus lesions.16
Traditional, fresh stored osteochondral allografts, which are
often used to treat larger articular cartilage lesions, are
used with several millimeters of subchondral bone attached,
Fig. 6 Coronal and sagittal magnetic resonance images of patient 3 who was treated for a medial femoral condyle lesion, taken (A, AA)
preoperatively, (B, BB) at 1 month postoperatively, and (C, CC) at 6 months postoperatively.
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resulting in stiff grafts that must match the contour of the host
cartilage surrounding the implant site. Harvesting and implant-
ing fresh osteochondral allografts with the proper contour
requires donor and recipient size matching, often taking time
to acquire the properly sized graft, and specialized instrumen-
tation and skill at the time of surgery. In contrast, theflexibility
of the CVOCA enables the allograft to fit to multiple contours,
allowing for immediate graft availability and a straightforward
implantation procedure. Preservation using a cryoprotective
agent such as glycerol or dimethyl sulfoxide has traditionally
yielded only 20 to 30% chondrocyte viability in cartilage
allografts with viable cells primarily located in the suprerficial
zone. Clinical improvements have been shown to be propor-
tional toviablechondrocyte content in transplantedosteochon-
dral allografts.23–28However, advances in the cryopreservation
technique and a porated design, which optimized cryoprotec-
tant penetration into the cartilage tissue, have resulted in high
cell viability within the CVOCA (mean viability after thawing
¼ 70.5%).10 Fresh osteochondral allografts are rarely implanted
earlier than 14 days postprocurement due to donor screen
requirements, and chondrocyte viability has been shown to
decrease with storage time, reaching 70% viability by
28 days.7,8,29,30 More recent studies have demonstrated high
cell viability can be retained for up to 63 days following
procurement by utilizing optimized storage conditions.31,32
The CVOCA is generally less expensive than a fresh osteochon-
dral allograft when treating lesions 4.5 cm2 or smaller. The
CVOCAranges from$3,500 for0.8cm2ofcoverageto$11,000 for
4.5 cm2 of coverage. In contrast, a fresh hemicondyle costs
approximately $12,000. A fresh osteochondral allograft is less
expensive per square centimeter, making it more cost effective
for large lesions. Long-term clinical outcomes and costs of the
CVOCA in comparison to fresh osteochondral allografts remain
to be evaluated.
The most similar treatment option to the CVOCA that is
currently available in the United States is particulated juve-
nile allograft cartilage (DeNovo NT Graft, Zimmer Biomet),
another off-the-shelf allograft cartilage product. In contrast
to the CVOCA, this product is harvested from juvenile donors
(vs. adult donors), minced into small pieces (vs. zonal
structure intact), stored fresh in media at room temperature
for up to 49 days after procurement (vs. cryopreserved
within 4 days of procurement and stored for up to 2 years
at 80°C), and implanted without marrow stimulation to
augment the repair (vs. option to perform marrow stimula-
tion).33 The cost per surface area of a treated defect for the
two treatment options is similar.33,34 Although patient-re-
ported outcomes following implantation of the particulated
juvenile allograft cartilage are promising, the repair tissue
often has a cobblestone-like appearance as the minced
cartilage loses the biologically important zonal orientation
of the superficial, transitional, and radial zones.33,35,36 Alter-
natively, structural maintenance within the CVOCA has been
shown to translate to properly oriented repair tissue with
distinct superficial, translational, and radial zones upon
histological analysis in a preclinical animal model and a
clinical biopsy.10,15 Larger studies with long-term outcomes
are needed to better compare the two relatively new articu-
lar cartilage treatment options.
Although the outcomes highlighted in this report are
early, all three patients treated with the CVOCA were satis-
fied with their resolution of symptoms. The surgical techni-
que presented here for the knee has been applied to articular
cartilage lesions in the talus16 and may be applicable to
articular cartilage lesions in additional locations as well.
Overall, the CVOCA builds upon the well-documented posi-
tives and negatives of two well-established techniques,
marrowstimulation, and traditional osteochondral allograft-
ing, to offer surgeons a new treatment option for articular
cartilage repair. Results presented in this study suggest that
the CVOCA is safe for further long-term studies including a
control/cohort and validated functional outcomes. Such
studies are necessary to gain a better understanding of the
clinical outcomes and pharmacoeconomical impacts of the
CVOCA.
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